Sergio Rutella, MD, PhD, FRCPath, hematologist and professor of cancer immunotherapy at the John van Geest Cancer Research Centre, reports new findings from his work on acute myeloid leukemia (AML) patients carrying TP53 mutations. High T-cell infiltration, immune checkpoint expression, and interferon gamma signaling molecule levels were detected in this subset of patients. Initial studies using flotetuzumab to treat relapsed or refractory AML in patients with TP53 mutations had a 60% overall response rate.